Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.

Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.

Item

http://www.wikidata.org/entity/Q30513617

Q30513617

about

Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors Adverse Effects of GLP-1 Receptor Agonists Something old, something new and something very old: drugs for treating type 2 diabetes Incretins and the intensivist: what are they and what does an intensivist need to know about them?Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors Mouse pancreas tissue slice culture facilitates long-term studies of exocrine and endocrine cell physiology in situ Extended exenatide administration enhances lipid metabolism and exacerbates pancreatic injury in mice on a high fat, high carbohydrate diet Response to comments on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:25 Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.Divergent effects of liraglutide, exendin-4, and sitagliptin on beta-cell mass and indicators of pancreatitis in a mouse model of hyperglycaemia A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs.Pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop.Chronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates.Effects of the glucagon-like peptide-1 receptor agonist liraglutide in juvenile transgenic pigs modeling a pre-diabetic condition The double trouble of metabolic diseases: the diabetes-cancer link.Effectiveness and Persistence with Liraglutide Among Patients with Type 2 Diabetes in Routine Clinical Practice--EVIDENCE: A Prospective, 2-Year Follow-Up, Observational, Post-Marketing Study.Increased Serum Insulin Exposure Does Not Affect Age or Stage of Pancreatic Adenocarcinoma Diagnosis in Patients With Diabetes Mellitus.GPR40 modulators: new kid on the block Glucagon-Like Peptide-1 Receptor Expression in Normal and Neoplastic Human Pancreatic Tissues Proglucagon-Derived Peptides Do Not Significantly Affect Acute Exocrine Pancreas in Rats Acting on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A Timely Challenge Illustrated with GLP-1R and GPER No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks.Synergy Between Gαz Deficiency and GLP-1 Analog Treatment in Preserving Functional β-Cell Mass in Experimental Diabetes.A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?Global gene expression profiling of pancreatic islets in mice during streptozotocin-induced β-cell damage and pancreatic Glp-1 gene therapy.Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls.Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604 Dipeptidyl Peptidase-4 Inhibitor Use Is Not Associated With Acute Pancreatitis in High-Risk Type 2 Diabetic Patients: A Nationwide Cohort Study High-fat, high-calorie diet promotes early pancreatic neoplasia in the conditional KrasG12D mouse model.Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy.PSCs and GLP-1R: occurrence in normal pancreas, acute/chronic pancreatitis and effect of their activation by a GLP-1R agonist.One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice.Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum.Do GLP-1-based therapies increase cancer risk?Pathogenesis of pancreatic cancer: lessons from animal models.Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation.Incretin therapy and pancreatic pathologies: background pathology versus drug-induced pathology in rats.GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.Pancreatitis: a potential complication of liraglutide?

P2860

Q24568148-90EB8DDF-D3DB-4025-BC97-B214D04D7B17 Q24598747-F7C8FA6E-D382-47C0-80A7-6DA5D16137DA Q26801346-5B35613F-7FBE-4624-8521-50585B99886B Q26865663-14976597-5514-4C08-B934-67878F34B94C Q26995464-BED608A6-9CCF-4E06-A32D-DB4195C00CC0 Q27021870-4892E43A-B4A3-4CE2-9F2D-8B5CB392BC4B Q27302989-63D922F3-4DCD-49AF-91A8-07EE6121837A Q27339590-6BE5EDBA-E355-48BD-BF2F-23CC072365C4 Q28679307-A9027686-05BD-4118-960E-8536C30ACE06 Q31167862-E9011162-9571-4DDE-9B93-AB2F7CEA58D0 Q34041974-1A525E82-12F2-4D9C-9ADF-20A3EA5400B8 Q34543028-AA51CED0-2B72-4B8B-869F-F633F6D2B3AA Q34656874-474C26F3-6DED-485B-905B-977A29CEF074 Q34780873-EC0FD98A-45CC-4CD1-BF92-CF91F797EDC7 Q35184904-EC625F68-CB69-47EC-9EB8-8AB3BEF48AFC Q36058422-1A80AF64-F58B-4FC5-99AD-7211F9B169F8 Q36158841-286A285C-14F4-412F-8E27-7461B918103B Q36456052-100A9A37-ABB7-4781-82C4-0DE21E84947B Q36560325-0D44E066-12B1-470A-8570-138D6B5076B7 Q36665328-8CAA8F55-8773-4F08-A352-A79B1124D2FF Q36763274-481EF42B-4BAC-48DE-8D3F-5E6D007DAB6A Q36800401-EE1510F0-878B-422E-BADF-D8A1CAC767F8 Q36845768-DC797E1A-1022-4E42-97D8-5AB74B91C15C Q36859559-5B35E98A-6BE3-4DA1-B022-AA92E893850C Q36942123-003B3F0E-2BAE-45CC-9B8E-EC7797DBB32B Q37137787-580EC611-2C76-4E9C-8C4B-CB7EBDCC49FF Q37193295-FC4D66C2-2C64-4744-9087-51C5AD2CD595 Q37193335-283EAC21-16FF-43BB-B7A4-D163F8232C81 Q37206067-2BD996A1-B6E9-4E3B-BF7C-3B5F8B0C05B1 Q37328486-70F006EE-43DF-4CF1-BB04-55BA00184C0E Q37402786-0F58126B-18C3-4982-9A9D-6A174E6121F2 Q37428774-42579B35-F6EC-470A-AFA8-62CFD62CEDD1 Q37476451-B9FB0177-B7D0-45E1-8644-9C37780DEDA1 Q37517909-568AB27D-CAE7-43D7-ACA0-FFD3BB2DC943 Q37577143-A87F0C4C-00C7-4300-9EAE-FB802C4BEA54 Q37589374-5245EB4B-0B13-4B53-BFF9-7D489FB295DC Q37635255-3FE8A537-BC44-45BB-89EA-8D30EDBA4522 Q37660923-F6943F16-0EE5-432D-9772-434F5F4E27D5 Q38055195-6DBCB34A-84D7-46B2-AF14-646E72620AB0 Q38058498-F2A5182C-19EB-435E-9852-9C5ECB114DEE

P2860

Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.

Item

http://www.wikidata.org/entity/Q30513617

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu